Cell Products ⇢ Wild-type cells ⇢

Donor Panels

Unlock the Power of Diversity in Drug Discovery with DefiniGEN’s donor panel and iPSC line generation services

Understanding Population Variability

Drug efficacy and toxicology profiles often vary across populations due to genetic, environmental, physiological, and behavioral factors. Traditional models, such as animal studies and single-source in vitro liver models, fail to account for these differences, leading to limitations in early-stage drug development.

 

Through the Sanger Institute, DefiniGEN can access 330 wild-type donor panels, providing researchers a scalable, genetically diverse hepatocyte supply to enhance drug response predictions. 

 

def008_models_custom_v2

Key benefits

 green tick Diverse Donor Representation

Wide demographic range: Including different ages, genders, and ethnicities.

Genetic variability: Models capture unique donor-specific genetic markers.

 

 green tick Enhanced Predictive Power

Address variability in drug metabolism, efficacy, and toxicity.

Improve safety profiles and de-risk drug development.

 

 green tick Scalable for high-throughput investigations

Unlike Primary cells, iPSC-derived hepatocytes from DefiniGEN ensure consistent availability from the same donor. Allowing you to accelerate your research whilst also maintaining reproducibility.

 

 

Applications

Early Drug Development

Predict adverse drug responses early

Toxicology Studies

Identify variability in toxicity risk before clinical trials.

Precision Medicine

Tailor therapies to diverse population subsets

Technical data

Pluripotency and Morphology

DefiniGEN’s iPSC lines demonstrate consistent levels of pluripotency with defined colony morphology, maintaining quality across donors.

Fig1_a

Figure 1A: Representative brightfield pictures from DefiniGEN wild-type induced pluripotent stem cell lines (IPS-003: male donor, IPS-004: female donor, IPS-005: female donor) demonstrating compact and uniform iPSC colony morphology with defined edges and no evidence of spontaneous differentiation.

Fig1b_smaller
Figure 1B: mRNA expression levels of the key pluripotency markers NANOG, SOX2, and OCT4 in DefiniGEN wild-type induced pluripotent stem cell lines (IPS-003, IPS-004, IPS-005). mRNA data were normalized to GAPDH and are presented as mean±SEM of n=2 technical replicates.

Hepatocyte Maturity

Our Ulti-HEP models exhibit cobblestone-like morphology and express key hepatocyte markers such as albumin (ALB).

Fig2_a

Figure 2A: Representative brightfield pictures from DefiniGEN wild-type induced pluripotent stem cell-derived Ulti-HEP (-003, -004,-005) demonstrating the characteristic cobblestone-like hepatocyte morphology.

Fig2_b
Figure 2B: mRNA expression of the key hepatocyte maturity marker albumin (ALB) in DefiniGEN wild-type Ulti-HEP (-003, -004, -005). mRNA and secretion data were normalized to PPIA and ATP levels, respectively, and are presented as mean±SEM of n=1-3 biological replicates.
Fig2_c
Figure 2C: Secretion levels of the key hepatocyte maturity marker albumin in DefiniGEN wild-type Ulti-HEP (-003, -004, -005). mRNA and secretion data were normalized to PPIA and ATP levels, respectively, and are presented as mean±SEM of n=1-3 biological replicates.

CYP450 Expression and Activity

Donor-specific differences in Phase I CYP450 gene markers and basal CYP3A4 activity provide insights into individual drug metabolism profiles.

Fig3_a

Figure 3A: mRNA expression levels of Phase I CYP450 gene markers CYP3A4, CYP2B6, CYP2C9, CYP2A6, and CYP2C19 in DefiniGEN wild-type Ulti-HEP (-003, -004, -005).

Fig3_b

Figure 3B: Basal CYP3A4 activity in DefiniGEN wild-type Ulti-HEP (-003, -004, -005). mRNA and activity data were normalized to 18S rRNA and ATP levels, respectively, and are presented as mean±SEM of n=1-3 biological replicates.

DefiniGEN-logo

Ready to De-risk Your Drug Development Pipeline?

 

Get in touch to explore how DefiniGEN’s donor panels can elevate your drug discovery process.

Contact Us